Exakte Wirkstoffkennungen und zitierbare Passagen zu Wechselwirkungen, Gegenanzeigen und Nebenwirkungen.
Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
HYCAMTIN 1 mg powder for concentrate for solution for infusion HYCAMTIN 4 mg powder for concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 5
When combining topotecan with other chemotherapy agents, reduction of the doses of each medicinal
product may be required to improve tolerability. However, when combining with platinum agents,
there is a distinct sequence-dependent interaction depending on whether the platinum agent is given on
day 1 or 5 of the topotecan dosing. If either cisplatin or carboplatin is given on day 1 of the topotecan
dosing, a lower dose of each agent must be given to improve tolerability compared to the dose of each
agent which can be given if the platinum agent is given on day 5 of the topotecan dosing.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
When combining topotecan with other chemotherapy agents, reduction of the doses of each medicinal
product may be required to improve tolerability. However, when combining with platinum agents,
there is a distinct sequence-dependent interaction depending on whether the platinum agent is given on
day 1 or 5 of the topotecan dosing. If either cisplatin or carboplatin is given on day 1 of the topotecan
dosing, a lower dose of each agent must be given to improve tolerability compared to the dose of each
agent which can be given if the platinum agent is given on day 5 of the topotecan dosing. Currently
there is only limited experience in combining oral topotecan with other chemotherapy agents.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
When combining topotecan with other chemotherapy agents, reduction of the doses of each medicinal
product may be required to improve tolerability. However, when combining with platinum agents,
there is a distinct sequence-dependent interaction depending on whether the platinum agent is given on
day 1 or 5 of the topotecan dosing. If either cisplatin or carboplatin is given on day 1 of the topotecan
dosing, a lower dose of each agent must be given to improve tolerability compared to the dose of each
agent which can be given if the platinum agent is given on day 5 of the topotecan dosing.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Version 2026-03-31T11:50:00Z · SHA-256 51b338badc1d33edf5bf2700d056d46275447e6a3f83ae2173852608cc281250 · Passage 58d81a57b11ead3d73eb33334eb39df9103c652bbe12accd485c9d2a8c4e085a · Zeichen 386–979 im Abschnitt
Wechselwirkungen · Potactasol
Potactasol 1 mg powder for concentrate for solution for infusion Potactasol 4 mg powder for concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 5
When combining topotecan with other chemotherapy agents, reduction of the doses of each medicinal
product may be required to improve tolerability. However, when combining with platinum agents,
there is a distinct sequence-dependent interaction depending on whether the platinum agent is given on
day 1 or 5 of the topotecan dosing. If either cisplatin or carboplatin is given on day 1 of the topotecan
dosing, a lower dose of each agent must be given to improve tolerability compared to the dose of each
agent which can be given if the platinum agent is given on day 5 of the topotecan dosing.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Version 2025-01-20T15:29:00Z · SHA-256 c68b2e48aa64589388567936c88f944172f5a013496cba099e51d86c2816bef9 · Passage 58d81a57b11ead3d73eb33334eb39df9103c652bbe12accd485c9d2a8c4e085a · Zeichen 386–979 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.